|Description||Setipiprant is a potent, orally available and selective CRTH2 antagonist, which is a G protein-coupled receptor for PGD2. It may be a promising target for the treatment of allergic disorders. It was well tolerated and reduced both the allergen-induced LAR and the associated AHR in allergic asthmatics at multiple oral doses. It is a drug originally developed by Actelion, but it failed to show sufficient advantages and was discontinued from further development in this application. Later it was developed as a novel treatment for baldness by Kythera.|
|B0084-474875||25 mg||$198||In stock|
|Synonyms||2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid;ACT129968;2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid;8-Fluoro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5H-pyrido[4,3-b]indole-5-acetic acid;KYTH-105|
|Solubility||DMSO: ≥ 36 mg/mL|
|Application||Setipiprant may be a promising target for the treatment of allergic disorders.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||690.4±55.0 °C | Condition: Press: 760 Torr|
|Density||1.37±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Setipiprant is a drug originally developed by Actelion, but it failed to show sufficient advantages and was discontinued from further development in this application. Later it was developed as a novel treatment for baldness by Kythera.|
This active molecular is a selective chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) antagonist and is used for the trea...
PGD2-IN-1 is an antagonist of DP (IC50= 0.3 nM).
BI671800 is a CRTH2 antagonist. It is used to treat patients with asthma. It is associated with a small improvement in FEV1 in symptomatic controller-naïve asth...
AMG-009 is an orally active, small molecule dual D prostanoid(DP) receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antag...
This active molecular is a potent and selective D-prostanoid and CRTH2 inhibitor. IC50 values are 8 and 35 nM, respectively in plasma. Vidupiprant as an add-on ...
AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.
Setipiprant is a potent, orally available and selective CRTH2 antagonist, which is a G protein-coupled receptor for PGD2. It may be a promising target for the t...
AZ11665362 is a potent CRTH2 antagonist. It blocks the migration of eosinophils and basophils, and the rapid mobilization of eosinophils from bone marrow. It mi...